Fecal calprotectin concentration in the differential diagnosis of bowel diseases


Cite item

Full Text

Abstract

Aim. To estimate the informative value of a noninvasive fecal (calprotectin) test in the differential diagnosis of bowel diseases. Subjects and methods. One hundred and forty-two patients who had visited their physicians with intestinal disorders (a change in stool frequency and patterns, abdominal pain) were examined in an open-label multicenter cross-sectional study. The examinees' mean age was 35±2.43 years. Gender- and age-matched comparison groups consisted of healthy individuals and patients with irritable bowel syndrome. Fecal calprotectin (FCP) was determined using a BUHLMANN Calprotectin ELISA kit. All the patients underwent colonoscopy. Results. In the patients with organic bowel diseases (ulcerative colitis, Crohn's disease, lymphocytic colitis, colonic diverticular disease, colonic adenomas, celiac disease), the concentration of FCP was found to be substantially higher than that in the healthy individuals and patients with irritable bowel syndrome. The highest calprotectin levels were noted in the patients with inflammatory bowel diseases. Conclusion. This study demonstrated the high diagnostic value of the calprotectin test for the differential diagnosis of organic and functional bowel diseases.

References

  1. Sartor R.B., Sandborn W.I. Kirsner's inflammatory bowel diseases. 6th ed. London: Saunders 2004; 754.
  2. Van Assche G., Dignass A., Panes J. et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohn's Colit 2010; 4: 7-27.
  3. Hsu А. Antiinflamm Antiallergy Agents Med Chem 2009; 8 (4): 290-350.
  4. Roseth A.G., Aadland E., Jahnsen J., Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58 (2): 176-180.
  5. Долгих Т.И., Войтович М.А., Галилейская С.Б., Лазарева Л.И. Особенности диагностики кишечной инфекции, вызванной Escherichia coli О157, осложненной гемолитико-уремическим синдромом у детей раннего возраста в Омской области. Вестн Уральской медицинской академической науки 2009; 4: 119-120.
  6. Рекомендации по диагностике и лечению взрослых больных язвенным колитом, разработанные экспертной комиссией "Российской гастроэнтерологической ассоциации", ООО "Ассоциация колопроктологов России" и "Общества по изучению воспалительных заболеваний кишечника". 2013.
  7. Рекомендации по диагностике и лечению болезни Крона, разработанные Российской группой по изучению воспалительных заболеваний кишечника. 2009.
  8. -th Congress of Ecco - Inflammatory Bowel Diseases, Denmark, Copenhagen, 20 - 22 February 2014.
  9. van Rheenen P.F., Van de Vijver E., Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: 3369-3380.
  10. Gisbert J.P. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009; 41: 56-66.
  11. Burri E., Beglinger C. Faecal calprotectin - a useful tool in the management of inflammatory bowel disease. Swiss Med Wkly 2012 5; 142: w13557.
  12. Jensen M.D., Kjeldsen J., Nathan T. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol 2011; 46 (6): 694-700.
  13. Kok L., Elias S.G., Witteman B.J. et al. Diagnostic Accuracy of Point-of-Care Fecal Calprotectin and Immunochemical Occult Blood Tests for Diagnosis of Organic Bowel Disease in Primary Care: The Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) Study. Clin Chem 2012. PMID: 22407858.
  14. Manz M., Burri E., Rothen C. et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol 2012; 12 (1): 5.
  15. von Arnim U., Ganzert C., Wex T., Malfertheiner P. Faecal calprotectin: Useful for clinical differentiation of microscopic colitis and irritable bowel syndrome? Доступно на: https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2011/item/126.html
  16. Tursi A. Biomarkers in diverticular diseases of the colon. Dig Dis 2012; 30 (1): 12-18.
  17. Tibble J., G. Sigthorsson, R. Foster et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001; 49 (3): 402-408.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies